Immutep Limited
IMMPNASDAQHealthcareBiotechnology
Previous close
$0.3861
−$0.005 · -1.28%
IMMP company overview
Regular session · ET · Market data may be delayed.
GoAI snapshot
AI-powered factor overview
GoAI score
Sell
Trim exposure — unfavorable risk-reward
Valuation
56
Fair Value
Momentum
25
Weakening
Sentiment
40
Bearish
Risk resilience
21
High Risk
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
AI-generated, informational only, and not investment advice.
Company profile
Company websiteImmutep Limited, a biotechnology company, engages in developing novel Lymphocyte Activation Gene-3 related immunotherapies for cancer and autoimmune diseases in Australia. Its lead product candidate is the eftilagimod alfa (efti or IMP321), a soluble LAG-3lg fusion based on LAG-3 immune control mechanism for the treatment of different types of cancers. The company's product pipeline also includes TACTI-004, which is in phase III clinical trial for the treatment of first line non-small cell lung cancer (1L NSCLC); TACTI-003, which is in phase IIb clinical trial to treat first line head and neck squamous cell carcinoma (HNSCC); INSIGHT-005 which is in phase I for metastatic urothelial carcinoma; TACTI-002, which in phase II trial for the treatment NSCLC and HNSCC; AIPAC-003, which is in phase II/III clinical trial to treat metatastic breast cancer; and EFTISARC-NEO, which is in phase II clinical trial for the treatment of soft tissue sarcoma. It also develops INSIGHT-003, which is in phase I trial 1L non squamous NSCL; INSIGHT-005 that is in phase I to treat metastatic urothelial cancer; IMP761, which is in phase I Trial to treat autoimmune disease; IMP731 for oncology and autoimmune diseases; and LAG525. Immutep has collaboration with Merck & Co., Inc., EOC Pharma, Novartis, and Laboratory Corporation of America Holdings. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. The company was incorporated in 1987 and is based in Sydney, Australia.
- Industry
- Biotechnology
- Sector
- Healthcare
- Headquarters
- AU
- CEO
- Marc Voigt
- Listed since
- Apr 19, 2012
- Employees
- 53
Market position
Day range
Current $0.3861
52-week range
Current $0.3861
- Open
- $0.40
- Previous close
- $0.3911
- Volume
- 113.89K
- 0.18× average
- Average volume
- 627.13K
- Average daily volume
- Market cap
- 56.9M USD
- Beta
- 2.29
- Market reference 1
- 50-day average
- $0.3972
- -2.79% below average
- 200-day average
- $1.3539
- -71.48% below average
Financials
Financial snapshot
Latest / TTMValuation & yield
- Enterprise value
- 296.98M AUD
- P/E (TTM)
- -0.91×
- P/B (TTM)
- 0.77×
- P/S (TTM)
- 12.82×
- EV / EBITDA
- -4.72×
- Earnings yield
- -16.94%
- Free cash flow yield
- -17.12%
- Dividend yield
- 0.00%
Profitability & efficiency
- Gross margin
- -522.59%
- Operating margin
- -2052.18%
- Net margin
- -1404.13%
- Return on equity
- -42.77%
- Return on assets
- -39.13%
- Return on invested capital
- -86.87%
Financial health
- Debt / equity
- 0.02×
- Current ratio
- 11.69×
- Altman Z-score
- -5.81
- Piotroski F-score
- 3 of 9
Financial statements
Margin trends
Profitability as a percentage of reported revenue.
Income trends
Revenue
Operating income
Net income
| Metric (AUD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 5.04M AUD | 3.84M AUD | 3.51M AUD | 170.37K AUD | 3.86M AUD |
| Cost of goods sold | 61.41M AUD | 41.55M AUD | 2.06M AUD | 2.06M AUD | 17.24M AUD |
| Gross profit | −56.37M AUD | −37.7M AUD | 1.44M AUD | −1.89M AUD | −13.37M AUD |
| Research and development | 61.41M AUD | 41.55M AUD | 28.79M AUD | 31.34M AUD | 17.24M AUD |
| Selling, general, and administrative | 8.64M AUD | 8.85M AUD | 14.08M AUD | 7.21M AUD | 6.28M AUD |
| Operating expenses | 70.06M AUD | 50.4M AUD | 44.94M AUD | 32.55M AUD | 18.3M AUD |
| Interest income | 5.25M AUD | 3.88M AUD | 939K AUD | 224.52K AUD | 105.33K AUD |
| Interest expense | 24.01K AUD | 30.59K AUD | 20.4K AUD | 92.43K AUD | 9.83K AUD |
| Depreciation and amortization | 2.13M AUD | 2.01M AUD | 1.86M AUD | 1.84M AUD | 1.89M AUD |
| Operating income | −126.42M AUD | −88.1M AUD | −77.69M AUD | −33.94M AUD | −31.68M AUD |
| Net income | −61.43M AUD | −42.72M AUD | −39.9M AUD | −32.21M AUD | −29.9M AUD |
Company facts updated Aug 24, 2026.
Earnings
- EPS beat rate
- 64%
- 7 beats, 4 misses, 0 met estimates
- Average EPS surprise
- +23.65%
- 11 comparable reports
- Latest EPS result
- -0.22
- Estimate -0.2 · Miss by 9.90%
EPS: actual versus estimate
Recent quarterly results
Revenue: actual versus estimate
Recent quarterly results
Analyst ratings
Third-party consensus; not a GoAI recommendation.
Analyst price target
Average target
$4.25
1000.75% upsideRating distribution
4 ratingsLimited analyst sample: 4 ratings. Interpret the distribution with caution.
Recent analyst actions
IMMP news
Corporate actions
Corporate action history
| Action | Effective date | Details | Record date | Payment date |
|---|---|---|---|---|
Stock split | Nov 7, 2019 | 1:10 | — | — |
Stock split | Jul 15, 2019 | 1,011:1,000 | — | — |
Stock split | Dec 28, 2016 | 3:10 | — | — |
Effective Nov 7, 2019
1:10
Effective Jul 15, 2019
1,011:1,000
Effective Dec 28, 2016
3:10
IMMP peers
ETFs holding IMMP
Funds reporting this stock among their holdings, ordered by reported position size.
Continue in GoAI
Research IMMPresearch.disclaimer